The CONVERGE PAS study checks if a special device (EPi-Sense®) is safe and works well for people with a heart problem called atrial fibrillation (AF). AF makes your heart beat fast and can lead to strokes. This study is for people who tried other drugs but they didn't work or caused bad side effects.
The study involves a procedure called Hybrid Convergent, which treats AF by working on both the outside and inside of the heart. This approach has been used safely in about 10,000 patients. The study wants to confirm if this treatment is good for more people.
To join, you should be between 18 and 79 years old and have AF for more than a year. You should not be pregnant or have certain other heart or health problems.
- The study tracks long-term effects of the treatment.
- Participants are monitored to ensure safety and effectiveness.
- It aims to improve treatment guidelines for patients with AF.
How understandable was the trial content above?
Hard to understand
Easy to understand